Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Breast Cancer Res Treat. 2016 Nov 16;161(2):229–243. doi: 10.1007/s10549-016-4052-0

Figure 4. Promotion of ER turnover by HS5-CM.

Figure 4

A. Suppression of ER by HS5-CM was reversed by MG132 (5ug/ml). B. Anti-ubiquitin immunoblot of control- or HS5-CM exposed MCF7 cell lysates immunoprecipitated with Ig or anti-ER as noted. C. Decay curve for ER in control or HS5-CM. Time after cycloheximide as indicated, see text for details. Mean and SD of 4 experiments (2 for time points 0.5 and 8 hours). Difference between the change in ER/Ponceau over time between control and HS5-CM-treated cells was assessed by a mixed effects analysis of covariance model, as detailed in Supplementary Statistical Methods. D. Example blot from cycloheximide study. E. Inhibition of ER mRNA by HS5-CM. Representative RT-PCR of 3 endpoint and 2 qPCR experimental replicates.